Document:

Nonstatutory Stock Option Agreement

 Exhibit 10.1 
  
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF
1933. 
  
 COLLAGENEX PHARMACEUTICALS, INC. 
  
 STOCK OPTION AGREEMENT 
  
 CollaGenex Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), hereby grants to Andrew Powell (the “Optionee”) an Option (the “Option”) to purchase a total of 70,000 shares of the Company’s Common Stock (the “Shares”), at the price set forth
herein. 
  
 1. Nature of the Option. The Option is a
Nonstatutory Stock Option and is not intended to qualify for any special tax benefits to the Optionee. 
  
 2. Exercise Price. The exercise price is $6.70 for each share of Common Stock, which price is not less than the fair market value per share
of the Company’s Common Stock on the date of grant as determined by the Company’s Board of Directors. 
  
 “Fair Market Value” means, as of any date, the value of the Company’s Common Stock determined as follows:

  
 If the Common Stock is listed on any
established stock exchange or a national market system, including without limitation the Nasdaq National Market, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such
system or exchange for the last market trading day prior to the time of determination as reported in the Wall Street Journal or such other source as the Company’s Board of Directors deems reliable; or 
  
 If the Common Stock is quoted on Nasdaq (but not on the
National Market System thereof) or regularly quoted by a recognized securities dealer but selling prices are not reported, its Fair Market Value shall be the mean between the high and low asked prices for the Common Stock; or 
  
 In the absence of an established market for the Common
Stock, the Fair Market Value thereof shall be determined in good faith by the Company’s Board of Directors. 

 3. Exercise of Option. The Option shall be exercisable during its term in accordance with the
following: 
  
 (i) Right to Exercise 
  
 (a) Subject to subsections 3(i)(b), (c) and (d) below, all
of the Shares subject to the Option shall become exercisable based upon the following schedule until all of such Shares are exercisable: 
  

				
	Months from Vesting Date

	 	Percentage Exercisable

	 
	12	 	20	%
	24	 	20	%
	36	 	20	%
	48	 	20	%
	60	 	20	%

  
 (b)
The Option may not be exercised for a fraction of a Share. 
  
 (c) In the event of Optionee’s death, disability or termination as an Employee or Consultant, the exercisability of the Option is governed by Sections 7, 8, 9 and 10 below, subject to the limitations contained in
subsections 3(i)(d) hereof. 
  
 (d) In no event
may the Option be exercised after the date of expiration of the term of the Option as set forth in Section 12 below. 
  
 (ii) Method of Exercise. The Option shall be exercisable by written notice in the form attached as Exhibit A, which shall state the election to
exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements as to the holder’s investment intent with respect to such shares of Common Stock as may be required by
the Company. Such written notice shall be signed by Optionee and shall be delivered in person or by certified mail to the President, Secretary or Chief Financial Officer of the Company or such other agent designated in writing by the Company. The
written notice shall be accompanied by payment of the exercise price. The Option shall be deemed to be exercised upon receipt by the Company of such written notice accompanied by the exercise price. Until the issuance (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the stock certificate evidencing such Shares, no right to vote or receive dividends or any other rights as a shareholder shall exist with respect
to the shares of stock underlying the Option, notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such stock certificate promptly upon exercise of the Option. 
  

 - 2 - 

 No shares will be issued pursuant to the exercise of the Option unless such issuance and such exercise
shall comply with all relevant provisions of law and the requirements of any stock exchange upon which the Shares may then be listed. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the
date on which the Option is exercised with respect to such Shares. 
  
 4. Investment Representations; Restrictions on Transfer. 
  
 (i) By receipt of the Option, by its execution and by its exercise in whole or in part, Optionee represents to the Company the following: 
  
 (a) Optionee understands that the Option and any Shares purchased upon its exercise are securities, the
issuance of which requires compliance with federal and state securities laws. 
  
 (b) Optionee is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the securities.
Optionee is acquiring these securities for investment for Optionee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended
(the “Securities Act”). 
  
 (c)
Optionee acknowledges and understands that the securities constitute “restricted securities” under the Securities Act and must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such
registration is available. Optionee further acknowledges and understands that the Company is under no obligation to register the securities. Optionee understands that the certificate evidencing the securities will be imprinted with a legend which
prohibits the transfer of the securities unless they are registered or such registration is not required in the opinion of counsel satisfactory to the Company and any other legend required under applicable state securities laws. 
  
 (d) Optionee is familiar with the provisions of Rule 701 and
Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof, in a non-public offering subject to the
satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of exercise of the Option by the Optionee, such exercise will be exempt from registration under the Securities Act. In the event the
Company later becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), ninety (90) days thereafter the securities exempt under Rule 701 may be resold,
subject to the satisfaction of certain of the conditions specified by Rule 144, including among other things: (1) the sale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market
maker (as such term is defined under the 
  

 - 3 - 

 Exchange Act); and, in the case of an affiliate, (2) the availability of certain public information about
the Company, and the amount of securities being sold during any three-month period not exceeding the limitations specified in Rule 144(e), if applicable. Notwithstanding this paragraph 4(i)(d), the Optionee acknowledges and agrees to the
restrictions set forth in paragraph 4(ii) below. 
  
 In the event that the Company does not qualify under Rule 701 at the time of exercise of the Option, then the securities may be resold in certain limited circumstances subject to the provisions of Rule 144, which requires among other
things: (1) the availability of certain public information about the Company; (2) the resale occurring not earlier than the time period prescribed by Rule 144 after the party has purchased, and made full payment for, within the meaning of Rule 144,
the securities to be sold; and (3) in the case of an affiliate, or of a non-affiliate who has held the securities less than the time period prescribed by Rule 144, the sale being made through a broker in an unsolicited “broker’s
transaction” or in transactions directly with a market maker (as such term is defined under the Exchange Act) and the amount of securities being sold during any three month period not exceeding the specified limitations stated therein, if
applicable. 
  
 (ii) Optionee agrees, in connection with an
underwritten public offering of the Company’s securities, (1) not to sell, make short sale of, loan, grant any options for the purchase of, or otherwise dispose of any shares of Common Stock of the Company held by Optionee (other than those
shares included in the registration) without the prior written consent of the underwriters managing such underwritten public offering of the Company’s securities for a period of one hundred eighty (180) days from the effective date of such
registration (the “Lock Up Period”), and (2) further agrees to execute any agreement reflecting clause (1) above, or extending the Lock Up Period, as may be requested by the underwriters at the time of the public offering. 
  
 5. Method of Payment. Payment of the purchase price for the Shares
shall be made by cash or check. 
  
 6. Restrictions on
Exercise. The Option may not be exercised if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable federal or state securities or other law or
regulation. As a condition to the exercise of the option, the Company may require Optionee to make any representation and warranty to the Company as may be required by any applicable law or regulation. 
  
 7. Termination of Status as an Employee or Consultant. Except as set
forth below, in the event of termination of Optionee’s status as an Employee or Consultant of the Company, Optionee may, but only within ninety (90) days after the date of such termination (but in no event later than the date of expiration of
the term of the Option as set forth in Section 12 below), exercise the Option to the extent that Optionee was entitled to exercise it at the date of such 
  

 - 4 - 

 termination. To the extent that Optionee was not entitled to exercise the Option at the date of such termination, or if
Optionee does not exercise the Option within the time specified herein, the Option shall terminate. 
  
 8. Disability of Optionee. Notwithstanding the provisions of Section 7 above, in the event of termination of Optionee’s status as an Employee
or Consultant of the Company as a result of Optionee’s permanent and total disability (as defined in Section 22(e)(3) of the Internal Revenue Code of 1986, as amended), Optionee may, but only within twelve (12) months from the date of
termination of Optionee’s employment or consulting relationship with the Company (but in no event later than the date of expiration of the term of the Option as set forth in Section 12 below), exercise the Option to the extent Optionee was
entitled to exercise it at the date of such termination. To the extent that Optionee was not entitled to exercise the Option at the date of termination, or if Optionee does not exercise the Option (which Optionee was entitled to exercise) within the
time specified herein, the Option shall terminate. 
  
 9. Death
of Optionee. In the event of the death of Optionee: 
  
 (i)
during the term of the Option while an Employee or Consultant of the Company and having been an Employee or Consultant since the date of grant of the Option, the Option may be exercised, at any time within twelve (12) months following the date of
death (but in no event later than the date of expiration of the term of the Option as set forth in Section 12 below), by Optionee’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the
extent the Optionee was entitled to exercise the Option at the date of death; or 
  
 (ii) in the event of Optionee’s death within thirty (30) days after the termination of Optionee’s status as an Employee or Consultant pursuant to Section 7 above, the Option may be exercised, at any time
within six (6) months following the date of death (but in no event later than the date of expiration of the term of the Option as set forth in Section 12 below), by Optionee’s estate or by a person who acquired the right to exercise the Option
by bequest or inheritance, but only to the extent of the right to exercise that had accrued at the date of termination. 
  
 10. Termination for Cause. Notwithstanding the provisions of Section 7 above, in the event of “Termination for Cause” of Optionee’s
status as an Employee or Consultant with the Company (as the case may be), the Option, whether vested or unvested, shall terminate as of the effective date of Optionee’s dismissal from the Company. In addition to the immediate forfeiture of the
Option upon termination for cause, Optionee shall automatically forfeit all shares underlying any exercised portion of the Option for which the Company has not yet delivered the share certificates, upon refund by the Company of the exercise price
paid by the Optionee for such Shares. 
  
 “Termination
for Cause” shall include, but not be limited to, a finding by the Company’s Board of Directors of the Optionee’s: (i) performance of duties in an 
  

 - 5 - 

 incompetent manner; (ii) commission of any act of fraud, insubordination, misappropriation or personal
dishonesty relating to or involving the Company in any material way; (iii) gross negligence; (iv) violation of any express direction of the Company or any material violation of any rule, regulation, policy or plan established by the Company from
time to time regarding the conduct of its employees or its business, if such violation is not remedied by the Optionee within 30 days of receiving notice of such violation from the Company; (v) violation of any obligation of Optionee’s status
as an Employee or Consultant with the Company that is demonstrably willful and deliberate on the Optionee’s part and is not remedied by the Optionee within 30 days after receiving notice of such violation from the Company; (vi) disclosure or
use of confidential information of the Company, other than as required in the performance of the Optionee’s duties; (vii) actions that are clearly contrary to the best interest of the Company; (viii) conviction of a crime constituting a felony
or any other crime involving moral turpitude, or no conviction, but the substantial weight of credible evidence indicates that the Optionee has committed such a crime; or (ix) the Optionee’s use of alcohol or any unlawful controlled substance
to an extent that it interferes with the performance of the Optionee’s duties. 
  
 11. Non-Transferability of Option. The Option may not be transferred in any manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of Optionee only by
Optionee. The terms of the Option shall be binding upon the executors, administrators, heirs, successors and assigns of Optionee. 
  
 12. Term of Option. Notwithstanding anything herein to the contrary, the Option may not be exercised more than ten (10) years from the date of
grant of the Option, and may be exercised during such term only in accordance with the terms of the Option. 
  
 13. Adjustments Upon Changes in Capitalization or Merger. Subject to any required action by the shareholders of the Company, the number of shares
of Common Stock covered by the Option shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of
the Common Stock, or any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be
deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Company’s Board of Directors, whose determination in that respect shall be final, binding and conclusive. Except as expressly
provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares
of Common Stock subject to the Option. 
  
 In the event of the
proposed dissolution or liquidation of the Company, the Company’s Board of Directors shall notify the Optionee at least fifteen (15) days prior to such proposed 
  

 - 6 - 

 action. To the extent it has not been previously exercised, the Option will terminate immediately prior to the
consummation of such proposed action. In the event of a merger or consolidation of the Company with or into another corporation or the sale of all or substantially all of the Company’s assets (hereinafter, a “merger”), the Option
shall be assumed or an equivalent option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation. In the event that such successor corporation does not agree to assume the Option or to substitute an
equivalent option, the Board of Directors shall, in lieu of such assumption or substitution, provide for the Optionee to have the right to exercise the Option, including Shares as to which the Option would not otherwise be exercisable. If the
Company’s Board of Directors makes the Option fully exercisable in lieu of assumption or substitution in the event of a merger, the Board of Directors shall notify the Optionee that the Option shall be fully exercisable for a period of fifteen
(15) days from the date of such notice, and the Option will terminate upon the expiration of such period. For the purposes of this paragraph, the Option shall be considered assumed if, following the merger, the Option or right confers the right to
purchase, for each Share of stock subject to the Option immediately prior to the merger, the consideration (whether stock, cash, or other securities or property) received in the merger by holders of Common Stock for each Share held on the effective
date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the merger was not
solely common stock of the successor corporation or its Parent, the Company’s Board of Directors may, with the consent of the successor corporation and the participant, provide for the consideration to be received upon the exercise of the
Option, for each Share of stock subject to the Option, to be solely common stock of the successor corporation or its Parent equal in Fair Market Value to the per share consideration received by holders of Common Stock in the merger or sale of
assets. 
  
 14. Withholding Tax Obligations. The Option
shall be subject to any applicable federal (including FICA), state and local tax withholding requirements. The Company shall have the right to require the Optionee to pay to the Company such amount to be withheld prior to the issuance or delivery of
any Shares in connection with the exercise of the Option. 
  
 Should the Optionee incur tax liability in connection with the Option, which tax liability is subject to tax withholding under applicable tax laws, and the Optionee is obligated to pay the Company an amount required to be withheld under
applicable tax laws, the Optionee may, at the discretion of the Company’s Board of Directors, satisfy the withholding tax obligation by electing to have the Company withhold from the Shares to be issued upon exercise of the Option, that number
of Shares having a Fair Market Value equal to the amount required to be withheld. The Fair Market Value of the Shares to be withheld shall be determined on the date that the amount of tax to be withheld is to be determined (the “Tax
Date”). 
  
 All elections by the Optionee to have Shares
withheld for this purpose shall be made in writing in a form acceptable to the Company’s Board of Directors and shall be subject to the following restrictions: 
  
 (i) the election must be made on or prior to the applicable Tax Date; 
  

 - 7 - 

 (ii) once made, the election shall be irrevocable as to the particular Shares of the Option as to which
the election is made; 
  
 (iii) all elections shall be subject to
the consent or disapproval of the Company’s Board of Directors; and 
  
 (iv) if the Optionee is subject to Rule 16b-3 under the Exchange Act, the election must comply with the applicable provisions of Rule 16b-3 and shall be subject to such additional conditions or restrictions as may be
required thereunder to qualify for the maximum exemption from Section 16 of the Exchange Act. 
  
 15. Taxation Upon Exercise of Option. Optionee understands that, upon exercise of the Option, Optionee will recognize income for tax purposes in an amount equal to the excess of the then fair market value of
the Shares over the exercise price. Optionee hereby agrees to notify the Company in writing within thirty (30) days after the date of any such disposition. Upon a resale of such Shares by the Optionee, any difference between the sale price
and the fair market value of the Shares on the date of exercise of the option will be treated as capital gain or loss. 
  
 16. Tax Consequences. The Optionee understands that any of the foregoing references to taxation are based on federal income tax laws and
regulations now in effect. The Optionee has reviewed with the Optionee’s own tax advisors the federal, state, local and foreign tax consequences of the transactions contemplated by this Agreement. The Optionee is relying solely on such advisors
and not on any statements or representations of the Company or any of its agents. The Optionee understands that the Optionee (and not the Company) shall be responsible for the Optionee’s own tax liability that may arise as a result of the
transactions contemplated by this Agreement. 
  
 17. Entire
Agreement. This Agreement constitutes the entire understanding and contract between the parties and supersedes any and all prior and contemporaneous, oral or written representations, communications, understandings, and agreements between the
parties relating to option grants prior to the date hereof. The parties acknowledge and agree that neither of the parties is entering into this Agreement on the basis of any representations or promises not expressly contained herein. 
  

							
	 DATE OF GRANT:
	  	 	 	 	 	 
				
	         9/23/04
	  	 	 	 	 	 
			
	 VESTING DATE:
	  	 	 	 COLLAGENEX PHARMACEUTICALS, INC.

				
	         9/23/04
	  	 	 	 By:
	 	 /s/ Nancy C. Broadbent

	 	  	 	 	 Name:
	 	 Nancy C. Broadbent

	 	  	 	 	 Title:
	 	 Chief Financial Officer

  

 - 8 - 

 OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO SECTION 3 HEREOF IS EARNED ONLY
BY CONTINUING SERVICE AS AN EMPLOYEE OR CONSULTANT OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THE OPTION, THE TRANSACTIONS CONTEMPLATED
HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS AN EMPLOYEE OR CONSULTANT FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE WITH OPTIONEE’S
RIGHT OR THE COMPANY’S RIGHT TO TERMINATE OPTIONEE’S EMPLOYMENT OR CONSULTING RELATIONSHIP AT ANY TIME, WITH OR WITHOUT CAUSE. 
  
 Optionee has had an opportunity to obtain the advice of counsel prior to executing the Option and fully understands all provisions of the Option. Optionee
hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors of the Company upon any questions arising under the Option. Optionee further agrees to notify the Company upon any change in the
residence address indicated below. 
  
 Dated:
            10/24/04             
  

			
	                     /s/ Andrew Powell

	                             (Signature)

	
	 Name:         Andrew Powell

	
	 Residence Address:

	  

	  

	  

	 Social Security No.
	 	  

 EXHIBIT A 
  
 NOTICE OF EXERCISE OF STOCK OPTION 
  
 TO: 
  
 FROM: 
  
 DATE: 
  

	RE:	Exercise of Stock Option 

  
 I hereby exercise my option to purchase
                     shares of Common Stock at $             per share
(total exercise price of $            ), effective today’s date. This notice is given in accordance with the terms of my Stock Option Agreement dated
                    , 20    . The option price and vested amount is in accordance with Sections 2 and 3 of the
Stock Option Agreement. 
  
 Attached is a check payable to
CollaGenex Pharmaceuticals, Inc. for the total exercise price of the shares being purchased. The undersigned confirms the representations made in Section 4 of the Stock Option Agreement. 
  
 Please prepare the stock certificate in the following name(s): 
  

  

  
 If the stock is to be registered in a name other than your name, please so
advise the Company. The Stock Option Agreement requires the Company’s approval for registration in a name other than your name and requires certain agreements from any joint owner. 
  

	
	 Sincerely,

	
	
 (Signature)

	
	
 (Print or Type Name)

  

			
	 Letter and consideration

	 received on
                    , 20    .

	
	 By:Asset Purchase and Product Development Agreement

 Exhibit 10.2 
  
 ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT 
  
 by and between 
  
 COLLAGENEX PHARMACEUTICALS INC. 
  
 and 
  
 THOMAS SKOLD 
  
 Dated as of August 19, 2004 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page

	 ARTICLE 1
	  	        DEFINITIONS	  	1
			
	 ARTICLE 2
	  	        PURCHASE AND SALE; CONSULTING ARRANGEMENT	  	6
			
	 2.1    
	  	Purchase and Sale of Purchased Assets	  	6
			
	 2.2    
	  	Excluded Assets	  	6
			
	 2.3    
	  	Purchase Price	  	6
			
	 2.4    
	  	Deliveries by Seller	  	7
			
	 2.5    
	  	Further Assurances	  	7
			
	 2.6    
	  	Consulting Agreement	  	7
			
	 ARTICLE 3
	  	        JOINT STEERING COMMITTEE; DEVELOPMENT PLAN; BUSINESS PLAN	  	7
			
	 3.1    
	  	Joint Steering Committee	  	7
			
	 3.2    
	  	Selection of and Responsibility for Development of Products	  	8
			
	 3.3    
	  	Development Plans	  	9
			
	 3.4    
	  	Development Diligence	  	9
			
	 3.5    
	  	Regulatory Approvals	  	9
			
	 3.6    
	  	Intellectual Property Rights	  	9
			
	 3.7    
	  	Commercialization and Business Plans	  	10
			
	 ARTICLE 4
	  	        FINANCIAL PROVISIONS	  	10
			
	 4.1    
	  	Milestone Payments	  	10
			
	 4.2    
	  	Royalties	  	10
			
	 4.3    
	  	Sublicense Income	  	11
			
	 4.4    
	  	Patent Defense Expense Set-Off	  	11
			
	 4.5    
	  	Statements and Payment	  	11
			
	 4.6    
	  	Taxes and Withholding	  	11
			
	 4.7    
	  	Payment Currency; Currency Exchange	  	11
			
	 4.8    
	  	Maintenance of Records; Audit	  	12
			
	 ARTICLE 5
	  	        REPRESENTATIONS, WARRANTIES AND COVENANTS	  	13
			
	 5.1    
	  	Mutual Representations, Warranties and Covenants	  	13
			
	 5.2    
	  	Additional Representations, Warranties and Covenants of Skold	  	13
			
	 5.3    
	  	Disclaimer of Warranties	  	14

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page

	 ARTICLE 6
	  	        CONFIDENTIALITY, PUBLICATION AND PUBLIC ANNOUNCEMENTS	  	14
			
	 6.1    
	  	Confidentiality	  	14
			
	 6.2    
	  	Authorized Disclosure	  	15
			
	 6.3    
	  	Return of Confidential Information	  	15
			
	 6.4    
	  	Unauthorized Use	  	15
			
	 6.5    
	  	Public Announcements	  	15
			
	 6.6    
	  	Injunctive Relief	  	15
			
	 ARTICLE 7
	  	        INDEMNIFICATION	  	16
			
	 7.1    
	  	CollaGenex	  	16
			
	 7.2    
	  	Skold	  	16
			
	 7.3    
	  	Indemnification Procedures	  	16
			
	 7.4    
	  	Insurance	  	17
			
	 7.5    
	  	Limitation of Liabilities.	  	18
			
	 ARTICLE 8
	  	        TERM AND TERMINATION	  	18
			
	 8.1    
	  	Term	  	18
			
	 8.2    
	  	Voluntary Termination by CollaGenex	  	18
			
	 8.3    
	  	Material Breach	  	18
			
	 8.4    
	  	Continuing Rights of Sublicensees	  	18
			
	 8.5    
	  	Effect of Termination	  	19
			
	 ARTICLE 9
	  	        MISCELLANEOUS	  	20
			
	 9.1    
	  	Dispute Resolution; Mediation	  	20
			
	 9.2    
	  	Assignment	  	21
			
	 9.3    
	  	Further Actions	  	21
			
	 9.4    
	  	Force Majeure	  	21
			
	 9.5    
	  	Notices	  	21
			
	 9.6    
	  	Amendment	  	22
			
	 9.7    
	  	Waiver	  	22
			
	 9.8    
	  	Counterparts; Facsimile Signatures	  	22
			
	 9.9    
	  	Descriptive Headings	  	22

 TABLE OF CONTENTS 
 (continued) 
  

					
	 	  	 	  	Page

	 9.10
	  	Governing Law	  	22
			
	 9.11
	  	Severability	  	22
			
	 9.12
	  	Entire Agreement of the Parties	  	22
			
	 9.13
	  	Independent Contractors	  	23
			
	 9.14
	  	Expenses	  	23
			
	 9.15
	  	No Third Party Beneficiaries	  	23
			
	 9.16
	  	No Strict Construction	  	23

 ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT 
  
 This ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT (the
“Agreement”), dated as of August 19, 2004 (the “Effective Date”), is made by and between CollaGenex Pharmaceuticals Inc., a Delaware corporation having its principal office at 41 University Drive, Newtown,
Pennsylvania, United States of America 18940 (“CollaGenex”), and Thomas Skold, a citizen and resident of Sweden of Bjorno Gard, S-761 41 Norrtalje, Sweden (“Skold”). CollaGenex and Skold are each sometimes referred
to individually as a “Party” and together as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, the
Parties entered into that certain Co-operation, Development and Licensing Agreement dated February 12, 2002 (the “Original Agreement”); 
  
 WHEREAS, the Parties desire to modify the terms of their relationship by terminating the Original Agreement and, simultaneously therewith, entering into
this Agreement; and 
  
 WHEREAS, in connection with such
modification of terms, CollaGenex desires to acquire from Skold the topical technology that Skold has developed, as more specifically described herein, and Skold desires to transfer to CollaGenex, such topical delivery technology. 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the
representations, covenants and agreements contained herein, CollaGenex and Skold, intending to be legally bound, hereby agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS

  
 When used in this Agreement, whether in the singular or
plural, each of the following capitalized terms shall have the meanings set forth in this Article 1. 
  
 1.1 “Affiliate” means a Person that, directly or indirectly, through one or more intermediates, controls, is controlled by, or is under
common control with, the Person specified. For the purposes of this definition, control shall mean the direct or indirect ownership of (i) in the case of corporate entities, securities authorized to cast more than fifty percent (50%) of the votes in
any election for directors, (ii) in the case of non-corporate entities, more than fifty percent (50%) ownership interest with the power to direct the management and policies of such non-corporate entity, or (iii) such lesser percentage as may be the
maximum percentage allowed to be owned by a foreign corporation under the applicable laws or regulations of a particular jurisdiction outside of the United States) of the equity having the power to vote in the election of directors or to direct the
management and policies of another entity. Notwithstanding the foregoing, the term “Affiliate” shall not include subsidiaries in which a Person or its Affiliates owns a majority of the ordinary voting power to elect a majority of
the board of directors, but is restricted from electing such majority by contract or otherwise, until such time as such restriction is no longer in effect. 

 1.2 “Books and Records” means copies of all books and records of Skold and its
Affiliates related to the Restoraderm Technology or the Purchased Assets. 
  
 1.3 “Additional Records” means any and all records or documentation in whatever form pertaining to the development, marketing or sales of a Product and originating from or generated by CollaGenex
under this Agreement such as, but not limited to, batch protocols, sterility protocols, clinical trial documentation, specification over raw materials and marketing materials. 
  
 1.4 “Business Day” means any day except Saturday and Sunday, on which commercial banking institutions in
New York are open for business. Any reference in this Agreement to “day”, whether or not capitalized, shall refer to a calendar day, not a Business Day. 
  
 1.5 “Commercially Reasonable Efforts” means, with respect to a Party, the efforts and resources which would
be used by that Party consistent with prevailing pharmaceutical industry standards for a company of similar size and scope to such Party with respect to a product or potential product at a similar stage in its development or product life and of
similar market potential, taking into account efficacy, safety, the anticipated Regulatory Authority approved labeling, the competitiveness of alternative products in the market place or under development, the patent and other proprietary position
of the product, the likelihood of Regulatory Approval, the commercial value of the product and other relevant factors. 
  
 1.6 “Confidential Information” means all secret, confidential or proprietary information or data, whether provided in written, oral,
graphic, video, computer or other form, provided by one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) pursuant to this Agreement or generated pursuant to this Agreement, including but not
limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications, business or products and any other information or materials that have not been made available by the Disclosing
Party to the general public. The terms of this Agreement shall also be deemed Confidential Information hereunder, except to the extent disclosed pursuant to Section 7.5 herein. Notwithstanding the foregoing sentences, Confidential Information shall
not include any information or materials that: 
  
 (a) were
already known to the Receiving Party (other than under an obligation of confidentiality) at the time of disclosure by the Disclosing Party to the extent such Receiving Party has documentary evidence to that effect; 
  
 (b) were generally available to the public or otherwise part of the public
domain at the time of its disclosure to the Receiving Party; 
  
 (c) became generally available to the public or otherwise part of the public domain after its disclosure or development, as the case may be, and other than through any act or omission of a Party in breach of such Party’s
confidentiality obligations under this Agreement; or 
  
 (d) were
subsequently lawfully disclosed to the Receiving Party by a Third Party who had no obligation to the Disclosing Party not to disclose such information or materials to others. 
  

 - 2 - 

 1.7 “Control,” “Controls,” “Controller” or
“Controlled” means with respect to Technology and/or Patent Rights, the ownership thereof, or the possession of the ability to grant licenses or sublicenses thereto without violating the terms of any agreement or other arrangement
with, or the rights of, any Third Party existing as of the date on which such license or sublicense is granted. 
  
 1.8 “FDA” means the United States Food and Drug Administration, or any successor agency thereof. 
  
 1.9 “First Commercial Sale” means the first sale by
CollaGenex or its Affiliates or sublicensees of a Product to a Third Party for end use or consumption of such Product after a Regulatory Authority has granted Regulatory Approval of such Product, if applicable. 
  
 1.10 “Force Majeure” means any occurrence beyond the
reasonable control of a Party that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder, if such occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor
dispute, casualty or accident; or war, revolution, civil commotion, acts of public enemies, terrorist attack, blockage or embargo; or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government (to the
extent such government has ruling authority over such Party) or of any subdivision, authority or representative of any such government; or other similar event, beyond the reasonable control of such Party, if and only if the Party affected shall have
used reasonable efforts to avoid such occurrence. 
  
 1.11
“Know-how” means, whether or not patented or patentable, all ideas, inventions, trade secrets, data, instructions, methods, techniques, assays, processes (including technology manufacturing processes), procedures, inventions,
know-how, data, designs, formulas, validations, documentation, technology, materials, equipment, specifications, and information. 
  
 1.12 “Losses” means any and all liabilities, damages, fines, penalties, deficiencies, losses and expenses (including interest, court
costs, amounts paid in settlement, reasonable fees of attorneys, accountants and other experts or other reasonable expenses of litigation or other proceedings or of any claim, default or assessment); provided, however, that the term
“Losses” shall not include any special, consequential, indirect, punitive, provisional or similar damages, except to the extent actually paid by a Party pursuant to any Third Party Claim. 
  
 1.13 “NDA” means a New Drug Application pursuant to 21
U.S.C. Section 505(b)(1) or Section 505(b)(2) submitted to the FDA or any successor application or procedure required for Regulatory Approval to commence sale of a Product. 
  
 1.14 “Net Sales” means the gross amounts received by CollaGenex or any of its Affiliates on account of
sales of Products to Third Parties (including without limitation Third Party distributors and wholesalers), less the total of: 
  
 (a) Trade, cash and/or quantity discounts actually allowed or accrued which are not already reflected in the amount invoiced; 
  

 - 3 - 

 (b) Excise, sales and other consumption taxes (including VAT on the sale of such Products) and custom
duties to the extent included in the invoice price and to the extent such taxes are remitted to the applicable taxing authority; 
  
 (c) Freight, insurance and other transportation charges to the extent included in the invoice price and separately identified on the invoice or other
documentation maintained in the ordinary course of business; 
  
 (d) Amounts repaid, credited or accrued by reason of returns, rejections, defects or recalls or because of chargebacks, retroactive price reductions, refunds or billing errors; 
  
 (e) Payments and rebates directly related to the sale of Products accrued, paid or deducted in a manner consistent with
generally accepted accounting principles (“GAAP”), pursuant to agreements with Third Parties or governmental regulations (including, but not limited to, those granted or given to managed health care organizations, wholesalers and
other distributors, buying groups, health care insurance carriers, or to federal, state and local governments); 
  
 (f) Amounts written off by reason of uncorrectable debt; 
  
 (g) Any royalties payable to Third Parties in the event that a Product contains one or more ingredients in which royalty amounts are to be paid on such
other ingredients; and 
  
 (h) Any other similar and customary
deductions taken in accordance with GAAP consistently applied. 
  
 Use of Products
for promotional, sampling or compassionate use purposes or for use in clinical trials shall not be considered in determining Net Sales. In the case of any sale of a Product between CollaGenex and its Affiliates for resale, Net Sales shall be
calculated as above only on the first arm’s length sale thereafter to a Third Party. 
  
 1.15 “Patent Rights” means all patents and patent applications and all patent applications hereafter filed, including any continuations, continuations-in-part, divisions, provisionals or any
substitute applications, non-provisional applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate) of any such patent, and any
confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing. 
  
 1.16 “Person” means any individual, firm, corporation, partnership, limited liability company, trust, unincorporated organization or
other entity or a government agency or political subdivision thereto, and shall include any successor (by merger or otherwise) of such Person. 
  
 1.17 “Product” means a product incorporating the Restoraderm Technology. 
  
 1.18 “Regulatory Approval” means the technical, medical and scientific licenses, registrations,
authorizations and approvals (including, without limitation, approvals of NDAs, 
  

 - 4 - 

 supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling
approvals) of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the development (including the conduct of clinical trials), manufacture,
distribution, marketing, promotion, offer for sale, use, import, reimbursement, export or sale of a Product in a regulatory jurisdiction. 
  
 1.19 “Regulatory Authority” means any national (e.g., the FDA), supra-national, regional, state or local regulatory agency,
department, bureau, commission, council or other governmental entity involved in the granting of Regulatory Approval in any country. 
  
 1.20 “Restoraderm Intellectual Property” means all (a) Restoraderm Patent Rights; (b) Restoraderm Know-How, and all rights in any
jurisdiction to limit the use or disclosure thereof; and (c) rights to sue and recover damages or obtain injunctive relief for past and future infringement, dilution, misappropriation, violation or breach thereof. 
  
 1.21 “Restoraderm Know-How” means any and all Know-How owned
or Controlled by Skold or its Affiliates as of the Effective Date relating to the Restoraderm Technology 
  
 1.22 “Restoraderm Patent Rights” means any and all Patent Rights owned or Controlled by Skold or its Affiliates as of the Effective Date
relating to the Restoraderm Technology. Schedule 1.22 contains those Patent Rights that have previously been assigned to CollaGenex by Skold, which Patent Rights are so specified under Schedule 1.22. 
  
 1.23 “Restoraderm Technology” means the topical drug
delivery technology developed by Skold and covered by the patent applications recited in Schedule 1.22. For the avoidance of doubt technology for oral, nasal or intravenous use shall not, when used in this Agreement, be embraced by the term
“topical”. 
  
 1.24 “Sublicense Income”
shall mean royalties actually received from a Third Party by CollaGenex on account of sales of Products by such Third Party in consideration for the grant of a sublicense to such third party under the Restoraderm Patent Rights. 
  
 1.25 “Third Party(ies)” means any Person other than Skold,
CollaGenex and their respective Affiliates. 
  
 1.26
“Trademark” or “Trademarks” means all trademarks, service marks, trade names, domain names, and registrations and applications for registration of the foregoing. 
  
 1.27 “Valid Claim” means a claim of an issued and unexpired
patent which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted to be invalid or unenforceable through
re-examination or disclaimer, opposition procedure, nullity suit or otherwise, which claim, but for the licenses granted herein, would be infringed by the sale of a Product. 
  

 - 5 - 

 ARTICLE 2 
 PURCHASE AND SALE; CONSULTING ARRANGEMENT 
  
 2.1 Purchase and Sale of Purchased Assets. Upon the terms and subject to the conditions set forth herein, on the Effective Date, Skold shall sell, transfer and deliver to CollaGenex, and cause its Affiliates to
sell, transfer and deliver to CollaGenex, free and clear of any encumbrances, and CollaGenex shall purchase from Skold and its Affiliates, Skold’s and its Affiliates’ full, complete and irrevocable right, title and interest in and to the
assets and rights of Skold and its Affiliates that are set forth below (collectively, the “Purchased Assets”) comprising all of the Skold’s and its Affiliates’ right, title and interest in the following: 
  
 (a) the Restoraderm Intellectual Property; 
  
 (b) the Books and Records relating to the Restoraderm Intellectual Property;

  
 (c) all rights and claims of Skold and its Affiliates against
Third Parties relating to the Purchased Assets, choate or inchoate, known or unknown, contingent or otherwise; and 
  
 (d) all goodwill, if any, relating to the foregoing. 
  
 2.2 Excluded Assets. Notwithstanding anything to the contrary contained herein, from and after the Effective Date, Skold and its Affiliates shall
retain all of the right, title and interest in and to, and there shall be excluded from the sale, assignment or transfer hereunder, and the Purchased Assets shall not include the following specifically enumerated assets (collectively, the
“Excluded Assets”): 
  
 (a) books and records
that Skold or its Affiliates are required to retain pursuant to any applicable law or regulations, other than the Books and Records; and 
  
 (b) general books of account and books of original entry that comprise Skold’s or its Affiliates’ permanent accounting or tax records.

  
 2.3 Purchase Price. The purchase price payable to Skold
(the “Purchase Price”) for the sale of the Purchased Assets shall be up to US $1,000,000 payable in United States Dollars as follows: 
  
 (a) US$150,000 within thirty (30) days after the Effective Date; 
  

(b) US$150,000 on January 31, 2005; and 
  
 (c) US$700,000 within thirty (30) days after the issuance of a patent covering the Restoraderm Technology, provided such issuance occurs after the First
Commercial Sale, provided further that if the patent issues prior to the First Commercial Sale, the payment pursuant to this Section 2.3(c) will be paid within thirty (30) days after the First Commercial Sale of the first Product, provided that if a
patent never issues, no amounts shall be due under this Section 2.3(c) and the sale and transfer of the Purchased Assets shall still occur pursuant to the terms of this Agreement. If CollaGenex makes a good faith determination for business reasons,
in its sole 
  

 - 6 - 

 discretion, to delay the launch of a commercially viable Product, then, provided that a patent has issued covering the
Restoraderm Technology, it will be deemed as if a First Commercial Sale has occurred and CollaGenex shall pay Skold the US$700,000 payment for such Product within thirty (30) days after such determination has been made. 
  
 2.4 Further Assurances. Skold shall execute and deliver (and shall
cause its Affiliates to execute and deliver) such additional instruments and other documents and use (and shall cause its respective Affiliates to use) all reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done,
all things necessary under applicable law or reasonably requested by CollaGenex to consummate the transactions contemplated hereby and to confirm and assure the transfer of the Purchased Assets to CollaGenex. 
  
 2.5 Consulting Agreement. On the Effective Date, Skold and CollaGenex
shall enter into a consulting agreement attached hereto as Exhibit A (the “Consulting Agreement”). Under the terms of the Consulting Agreement, Skold shall act as a consultant exclusively to CollaGenex regarding the
Restoraderm Technology. Any and all Patent Rights, Know-How, technology or other intellectual property rights, whether developed, conceptualized, generated and/or put into practice by Skold (individually or in conjunction with CollaGenex) during the
term of this Agreement or the Consulting Agreement relating to the Restoraderm Technology or any other topical drug delivery technology shall be the sole property of CollaGenex. Skold shall promptly notify CollaGenex, in writing, of any such Patent
Rights, Know-How, technology or other intellectual property rights, and Skold will assign and hereby does assign, complete and irrevocable right, title and interest in and to all such Patent Rights, Know-How, technology and other intellectual
property rights. 
  
 ARTICLE 3 
 JOINT STEERING COMMITTEE; DEVELOPMENT PLAN; BUSINESS PLAN 
  

3.1 Joint Steering Committee. 
  
 (a) Membership. Within thirty (30) days following the Effective Date, each of the Parties shall appoint two persons from their respective
organizations to serve on a joint steering committee (“Joint Steering Committee”), it being understood that in addition to Skold, Skold shall appoint an advisor or other designee to serve on the Joint Steering Committee, provided
such advisor and/or designee is reasonably acceptable to CollaGenex and is bound by obligations of confidentiality at least as stringent as those contained herein. Either Party may appoint, substitute or replace members of the Joint Steering
Committee to serve as their representatives upon notice to the other Party. The Joint Steering Committee shall be chaired by one of the CollaGenex representatives. Each representative of CollaGenex shall be entitled to one vote and each
representative of Skold shall be entitled to one vote. The Joint Steering Committee shall to the extent practicable seek to operate by consensus, provided that CollaGenex will have the tie-breaking vote on all Joint Steering Committee decisions.

  
 (b) Reserved. 
  
 (c) Responsibilities. The Joint Steering Committee shall perform the
following functions: (i) review and agree upon the Products to be developed; (ii) oversee the 
  

 - 7 - 

 development of the Products pursuant to the terms of this Agreement; (iii) review and agree upon the Development Plans
for Products and any material amendments to the Development Plans; and (iv) have such other responsibilities as may be assigned to the Joint Steering Committee pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to
time. 
  
 (d) Meetings. The Joint Steering Committee shall
regularly meet in person, by video or by teleconference (as mutually agreed by the Parties from time to time) twice a year or more frequently as may be agreed upon, to exercise its responsibilities. In order for a meeting of the Joint Steering
Committee to be convened, such meeting must include at least two (2) committee members of each Party and, provided this condition is met, a unanimous action taken at such meeting shall have been duly and validly taken by the Joint Steering
Committee. The first meeting of the Joint Steering Committee shall be convened within thirty (30) days from the Effective Date. CollaGenex shall reimburse Skold’s designee for reasonable out-of-pocket costs associated with such designee
attending any meeting of the Joint Steering Committee. 
  
 (e)
Agendas and Minutes for the Joint Steering Committee. Unless otherwise decided by the Joint Steering Committee, each Party will use reasonable efforts to disclose to the chair all proposed agenda items along with appropriate background or
supporting information at least twenty (20) working days in advance of a Joint Steering Committee meeting. The chair will use reasonable efforts to present an agenda with appropriate background or supporting information at least ten (10) working
days in advance of a Joint Steering Committee meeting. After each meeting of the Joint Steering Committee, the Party whose turn it was hosting such meeting will prepare, within ten (10) working days after each meeting (whether held in person, by
video or by telecommunication), the minutes reporting in reasonable detail the actions taken or to be taken by the Joint Steering Committee, or its designees, the attendees, the status of goals and achievements as well as issues requiring
resolution, and resolutions of previously reported issues, which minutes shall set forth all pertinent information presented during the meeting in form and content reasonably acceptable to the other Party and shall be signed by one of the Joint
Steering Committee representatives from each of the Parties. 
  
 (f) No Authority to Modify Agreement. The Joint Steering Committee shall have no authority to amend or waive compliance with the terms and conditions of this Agreement, or to approve actions of the Parties which are inconsistent with
this Agreement. 
  
 3.2 Selection of and Responsibility for
Development of Products. 
  
 (a) Proposals for
Products. At any time after the Effective Date, either Party may make a written proposal to the Joint Steering Committee regarding the development of a product. Such proposal shall include (i) any data and other information in its possession
which may be relevant to the use of the proposed product, and (ii) an outline of the major development activities required to obtain Regulatory Approval for such proposed Product in the United States, including a timeline for performing such
activities. Thereafter, the Joint Development Committee shall meet in order to review such proposal. 
  
 (b) Inclusion of Products. With respect to a proposal pursuant to Section 3.2(a), if the Joint Steering Committee accepts such proposal, such
proposed Product shall be developed by CollaGenex in accordance with the terms of this Agreement and the Development 
  

 - 8 - 

 Plan prepared by CollaGenex pursuant to Section 3.3 for such Product. If the Joint Steering Committee cannot agree on the
inclusion of any proposed Product for development by CollaGenex, CollaGenex shall have the final decision as to whether and which Products are developed by CollaGenex under the terms of this Agreement. It is acknowledged and agreed by the Parties
that CollaGenex is currently developing a benzoyl peroxide Product (the “BPO Product”) and a clobetasol product (the “Clobetasol Product”). 
  
 (c) Responsibility. CollaGenex shall have sole responsibility and use its Commercially Reasonable Efforts for
developing Products and shall bear all costs and expenses associated with the development of such Products. 
  
 3.3 Development Plans. Once the Joint Steering Committee agrees to include, or CollaGenex has selected, a Product for development, CollaGenex shall
prepare a development plan, including the clinical trials contemplated for each such Product (each, a “Development Plan”). No later than October 31 of each year following the first year of a Development Plan, CollaGenex shall update
each Development Plan and provide such Development Plan to the Joint Steering Committee for review and approval, provided that CollaGenex shall have the final-decision making authority with respect to any element of a Development Plan. 

 
 3.4 Development Diligence. CollaGenex shall use its Commercially
Reasonable Efforts in order to meet the following diligence obligations: 
  
 (a) On or before December 31, 2005, CollaGenex shall initiate development efforts on at least five Products; and 
  
 (b) On or before March 31, 2007, CollaGenex shall either (i) demonstrate that the initial formulation of each such Product maintains stability for a
period of six (6) months or (ii) incur at least US$75,000 in costs and expenses per such Product in the development activities attempting to demonstrate such stability. For the avoidance of doubt, CollaGenex, in its sole discretion, reserves the
right at any time to abandon development of a Product if CollaGenex has not yet incurred US$75,000 in development costs and expenses on such Product, provided that such abandoned Product shall not count as one of the five Products. 
  
 (c) Notwithstanding the foregoing, the Parties acknowledge and agree that
CollaGenex has satisfied the diligence obligations of paragraphs (a) and (b) above with respect to the Clobetasol Product and therefore CollaGenex shall only be required to satisfy the diligence obligations in this Section 3.4 on four (4) more
Products. 
  
 3.5 Regulatory Approvals. CollaGenex shall
have sole responsibility for the applications for Regulatory Approvals, manufacture, marketing and distribution of the Products as well as the sole discretion as to how to pursue applications for Regulatory Approvals, manufacture, market and
distribute the Products. Skold shall render CollaGenex such assistance, as may be reasonably requested or required by CollaGenex, regarding such applications for Regulatory Approval and the manufacture, marketing and/or distribution of Products.

  
 3.6 Intellectual Property Rights. CollaGenex, at its
sole discretion and expense, shall use Commercially Reasonable Efforts to develop, administrate, prosecute, procure and maintain all Restoraderm Intellectual Property Rights, including the Restoraderm Patent Rights, (including 
  

 - 9 - 

 their issuance, reissuance, reexamination and the defense of any interference, revocation or opposition proceedings)
claiming the composition of matter or manufacture of the Products or their use. CollaGenex shall solicit Skold’s advice and review of the nature and text of patent applications and important prosecution matters related to the Restoraderm
Intellectual Property Rights in reasonably sufficient time prior to filings thereof, and CollaGenex shall take into account Skold’s reasonable comments related thereto. 
  
 3.7 Commercialization and Business Plans. CollaGenex shall use its Commercially Reasonable Efforts to market and sell
all Products. CollaGenex shall prepare a plan for marketing research, marketing activities and sales of the Product (each, a “Business Plan”). CollaGenex shall provide each Business Plan, as well as any amendments or updates to any
such Business Plan that CollaGenex may make, to Skold for his information, review and comments. 
  
 ARTICLE 4 
 FINANCIAL PROVISIONS 
  
 4.1 Milestone Payments. With respect to each of the first five Products, CollaGenex shall pay the following milestone
payments (the “Milestone Payments”) within thirty (30) calendar days following the first occurrence of the specified event: 
  
 (a) Pilot Stability. One hundred thirty-three thousand U.S. Dollars ($133,000) upon CollaGenex’s receipt of data, in a form acceptable to
CollaGenex, that demonstrates the initial formulation of the Product is stable for at least six months. 
  
 (b) Clinical Batch Stability. One hundred thirty-three thousand U.S. Dollars ($133,000) upon completion of the manufacture of clinical batches of
the Product under current Good Manufacturing Practice conditions with demonstrated stability based on twelve months of data at a pre-specified temperature. 
  
 (c) Technology Transfer to a Commercial Facility. One hundred thirty-four thousand U.S. Dollars ($134,000) upon completion of the manufacturing of
three batches of the Product under current Good Manufacturing Practices and in accordance with requirements for filing an NDA, irrespective of whether it is intended that an NDA will be filed for such Product, with demonstrated stability based on
twelve months of data at a pre-specified temperature. 
  
 Upon
achievement of a milestone for a particular Product, any previous Milestone Payment for that Product for which payment was not made shall be deemed achieved and payment therefore shall be made. For the avoidance of doubt, the Milestone Payments
shall be due only one time for each of the first five Products with different active ingredients regardless of how many line extensions, indications or dosage strengths are developed for Products with the same active ingredient. Milestone Payments
are only payable on the first five Products with different active ingredients, and no further Milestone Payments shall be due or owing to Skold regardless of the number of Products subsequently developed. 
  
 4.2 Royalties. Subject to the provisions of this Article 4, CollaGenex
shall pay Skold a five percent (5%) royalty on Net Sales of Products covered by a Valid Claim of the Restoraderm Patent Rights; provided, however, if CollaGenex, in order to make, use, sell or otherwise dispose of Products reasonably determines that
it must make payments to one or more 
  

 - 10 - 

 Third Parties to obtain license or similar rights, CollaGenex may reduce the royalties due Skold by half of the amount of
such third party payment, but not to such extent that the royalties due to Skold decreases below half the royalty earned. 
  
 4.3 Sublicense Income. CollaGenex shall pay to Skold twenty-five percent (25%) of all Sublicense Income that CollaGenex receives.

  
 4.4 Patent Defense Expense Set-Off. Subject to Section
3.6, CollaGenex may prosecute any Third Party believed to be infringing the Restoraderm Patent Rights and/or defend and control any action (or counterclaim or any defense asserted in any other CollaGenex’s action) initiated by a Third Party
(such as interference, revocation or opposition proceedings) alleging the invalidity or unenforceability of any Restoraderm Patent Right (each, a “Restoraderm Patent Right Action”). To the extent CollaGenex incurs any out-of-pocket
costs or expenses in the filing, prosecution or defense of any such Restoraderm Patent Right Action, CollaGenex shall be entitled to deduct thirty percent (30%) of any such costs or expenses from amounts that are otherwise due Skold under this
Article 4. 
  
 4.5 Statements and Payment. CollaGenex shall
deliver to Skold, within thirty (30) days after the end of each calendar quarter, a report setting forth for such calendar quarter the following information for each Product: (i) Net Sales of such Product on a country-by-country basis; (ii) the
basis for any adjustments to the royalties payable on account of sales of such Product in any country; (iii) the royalties due to Skold on account of sales of such Product; (iv) the Sublicense Income payments due Skold on account of sales of such
Product; and (iv) the exchange rates used in calculating any of the foregoing. CollaGenex shall make payment in conjunction with such report, as set forth in Section 4.7. 
  
 4.6 Taxes and Withholding. Any payments made by CollaGenex to Skold under this Agreement shall be reduced by the
amount required to be paid or withheld pursuant to any applicable law, including, but not limited to, United States federal, state or local tax law (“Withholding Taxes”). Any such Withholding Taxes required by law to be paid or
withheld shall be an expense of, and borne solely by, Skold. CollaGenex, as applicable, shall submit to Skold reasonable proof of payment of the Withholding Taxes, together with an accounting of the calculations of such taxes, within thirty (30)
days after such Withholding Taxes are remitted to the proper authority. The Parties will cooperate reasonably in completing and filing documents required under the provisions of any applicable tax laws or under any other applicable law in connection
with the making of any required tax payment or withholding payment, or in connection with any claim to a refund of or credit for any such payment. 
  
 4.7 Payment Currency; Currency Exchange. All payments made by CollaGenex to Skold hereunder shall be in United States dollars. With respect to Net
Sales invoiced or expenses incurred in U.S. dollars, the Net Sales or expense amounts and the amounts due to Skold hereunder shall be expressed in U.S. dollars. With respect to Net Sales invoiced or expenses incurred in a currency other than U.S.
dollars, the Net Sales or expense shall be expressed in the domestic currency of the entity making the sale or incurring the expense, together with the U.S. dollar equivalent, calculated using the arithmetic average of the spot rates on the last
Business Day of each month of the calendar quarter in which the Net Sales were made or the expense was incurred. The “closing mid-point rates” found in the “Dollar spot forward 
  

 11 

 against the Dollar” table published by The Financial Times, or any other publication as agreed to by the
Parties, shall be used as the source of spot rates to calculate the average as defined in the preceding sentence. All payments shall be made by wire transfer in U.S. dollars to the credit of such bank account as shall be designated at least five (5)
Business Days in advance by Skold in writing to CollaGenex. 
  
 4.8 Maintenance of Records; Audit. For a period of two (2) years after the date of the invoice, CollaGenex shall maintain, and shall require its respective Affiliates to maintain, complete and accurate books and records in connection
with the sale of Products hereunder, as necessary to allow the accurate calculation consistent with generally accepted accounting principles of the royalties and Sublicense Income payments due to Skold, including any records required to calculate
any royalty adjustments hereunder. Once per calendar year, Skold shall have the right to engage an independent accounting firm reasonably acceptable to CollaGenex, which shall have the right to examine in confidence the relevant CollaGenex records
as may be reasonably necessary to determine and/or verify the amount of royalties and Sublicense Income payments due hereunder. Such examination shall be conducted, and CollaGenex shall make its records available, during normal business hours, after
at least fifteen (15) days prior written notice to CollaGenex, as applicable, and shall take place at the facility(ies) where such records are maintained. Each such examination shall be limited to pertinent books and records for any year ending not
more than twenty-four (24) months prior to the date of request; provided that Skold shall not be permitted to audit the same period of time more than once. Before permitting such independent accounting firm to have access to such books and records,
CollaGenex may require such independent accounting firm and its personnel involved in such audit, to sign a confidentiality agreement (in form and substance reasonably acceptable to CollaGenex) as to any confidential information which is to be
provided to such accounting firm or to which such accounting firm will have access, while conducting the audit under this paragraph. The Skold independent accounting firm will prepare and provide to each Party a written report stating whether the
royalties and Sublicense Income payment reports submitted and royalties and Sublicense Income payments paid are correct or incorrect and the details concerning any discrepancies. Such accounting firm may not reveal to Skold any information learned
in the course of such audit other than the amount of any such discrepancies. Skold agrees to hold in strict confidence all information disclosed to it, except to the extent necessary for Skold to enforce its rights under this Agreement or if
disclosure is required by law. In the event there was an underpayment by CollaGenex hereunder, CollaGenex shall promptly (but in no event later than thirty (30) days after such Party’s receipt of the independent auditor’s report so
correctly concluding) make payment to Skold of any shortfall. In the event that there was an overpayment by CollaGenex hereunder, Skold shall promptly (but in no event later than thirty (30) days after Skold’s receipt of the independent
auditor’s report so correctly concluding) refund to CollaGenex or credit to future royalties, at CollaGenex’s election, the excess amount. Skold shall bear the full cost of such audit unless such audit discloses an underreporting by
CollaGenex of more than ten percent (10%) of the aggregate amount of royalties and Sublicense Income payments in any twelve (12) month period, in which case, CollaGenex shall bear the full cost of such audit. 
  

 - 12 - 

 ARTICLE 5 
 REPRESENTATIONS, WARRANTIES AND COVENANTS 
  
 5.1 Mutual Representations, Warranties and Covenants. Each of Skold and CollaGenex hereby represents, warrants and covenants to the other Party as follows: 
  
 (a) It is duly organized and validly existing, or is a citizen and resident,
as applicable, and in good standing under the laws of such Party’s respective jurisdiction. It has the requisite legal power and authority to conduct its business as presently being conducted and as proposed to be conducted by it and is duly
qualified to do business in those jurisdictions where its ownership of property or the conduct of its business requires; 
  
 (b) It has all requisite legal power and authority to enter into this Agreement and to perform the obligations contemplated hereunder. All actions on its
part necessary for (i) the authorization, execution, delivery and performance by it of this Agreement, and (ii) the consummation of the transactions contemplated hereby, have been duly taken; 
  
 (c) This Agreement is a legally valid and binding obligation of it,
enforceable against it in accordance with its terms (except in all cases as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting the enforcement of creditors’ rights
generally and except that the availability of the equitable remedy of specific performance or injunctive relief is subject to the discretion of the court or other tribunal before which any proceeding may be brought); 
  
 (d) None of the execution and delivery of this Agreement, the consummation of
the transactions provided for herein or contemplated hereby, or the fulfillment by it of the terms hereof or thereof, will (with or without notice or passage of time or both) (i) conflict with or result in a breach of any provision of any
certificate or articles of incorporation or formation, by-laws, statutes, operating agreement or other governing documents of it, (ii) result in a default, constitute a default under, give rise to any right of termination, cancellation or
acceleration, or require any consent or approval (other than approvals that have heretofore been obtained) of any governmental authority or under any of the terms, conditions or provisions of any material note, bond, mortgage, indenture, loan,
arrangement, license, agreement, lease or other instrument or obligation to which it is a party or by which its assets may be bound, (iii) violate any law, rule or regulation of any governmental authority or stock exchange on which such Party’s
securities are listed applicable to it or any of its assets, or (iv) any other contractual or other obligations of the respective Party; and 
  
 (e) it shall comply in all material respects with all laws, rules and regulations applicable to its performance under this Agreement. 
  
 5.2 Additional Representations, Warranties and Covenants of Skold.
Skold hereby further represents, warrants and covenants to CollaGenex that: 
  
 (a) There are no existing or threatened actions, suits or other proceedings pending against him with respect to Restoraderm Intellectual Property Rights and, Skold has not received written notice of any threatened
claims or litigation seeking to invalidate the Restoraderm Patent Rights; 
  

 - 13 - 

 (b) Skold is not aware of any facts from which it reasonably concludes that any of the Restoraderm Patent
Rights are invalid or that their exercise would infringe patent rights of Third Party(ies); 
  
 (c) Skold holds good title to and is the legal and beneficial owner and has full and unencumbered rights to the Restoraderm Intellectual Property, free and clear of all liens, security interests, charges and other
encumbrances of any kind, and Skold has obtained the assignment of all interests and all rights of any and all Third Parties (including employees) with respect to the Restoraderm Patent Rights; 
  
 (d) Skold is the exclusive owner of all right, title and interest in the
Restoraderm Intellectual Property Rights; 
  
 (e) Skold will
perform his obligations under this Agreement in a professional, diligent and workmanlike manner in accordance with the standards which would be used by a physical person of similar financial strength, business experience and other relevant factors;
and 
  
 (f) to the best of Skold’s knowledge,
CollaGenex’s use of the Restoraderm Intellectual Property does not and will not infringe the intellectual property rights of any Third Party, and Skold has no knowledge that any Third Party is infringing any of the Restoraderm Intellectual
Property. 
  
 5.3 Disclaimer of Warranties. EXCEPT AS
OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR MANDATED BY APPLICABLE LAW (WITHOUT THE RIGHT TO WAIVE OR DISCLAIM), NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY WITH RESPECT TO THE PRODUCTS, ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS, SUCCESS
OR POTENTIAL SUCCESS OF THE DEVELOPMENT, COMMERCIALIZATION, MARKETING OR SALE OF ANY PRODUCT OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ALL WARRANTIES, CONDITIONS OR REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING IMPLIED
WARRANTIES OF PERFORMANCE, MERCHANTABILITY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
  
 ARTICLE 6 
 CONFIDENTIALITY, PUBLICATION AND PUBLIC ANNOUNCEMENTS 
  
 6.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, CollaGenex and Skold agree that, until seven (7) years after the termination of this Agreement, each of CollaGenex or
Skold, upon receiving or learning of any Confidential Information of the other Party, shall keep such Confidential Information confidential and otherwise shall not disclose or use such Confidential Information for any purpose other than as provided
for in this Agreement. The Receiving Party shall advise its employees and consultants who might have access to the Disclosing Party’s Confidential Information of the confidential nature thereof and agrees that its employees shall be bound by
the terms of this Agreement. The Receiving Party shall not disclose any Confidential Information of 
  

 - 14 - 

 the Disclosing Party to any employee who does not have a need for such information. It is acknowledged and agreed that
the Purchased Assets shall be the Confidential Information of CollaGenex. 
  
 6.2 Authorized Disclosure. Notwithstanding the foregoing, each of CollaGenex and Skold may disclose Confidential Information of the other Party to a Third Party to the extent such disclosure is reasonably
necessary to exercise the rights granted to or retained by it under this Agreement in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable governmental regulations, submitting information to tax
or other governmental authorities (including Regulatory Authorities), or conducting clinical trials hereunder with respect to Products, provided that if a Party is required by law to make any such disclosure of the Disclosing Party’s
Confidential Information, to the extent it may legally do so, it will give reasonable advance notice to the Disclosing Party of such disclosure and, save to the extent inappropriate in the case of patent applications or otherwise, will use its
reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). If the Disclosing Party has not filed a patent application with respect to such
Confidential Information, it may require the Receiving Party to delay the proposed disclosure (to the extent the disclosing party may legally do so), for up to ninety (90) days, to allow for the filing of such an application. 
  
 6.3 Return of Confidential Information. Upon termination of this
Agreement, the Receiving Party shall promptly return all of the Disclosing Party’s Confidential Information, including all reproductions and copies thereof in any medium, except that the Receiving Party may retain one copy for its legal files.

  
 6.4 Unauthorized Use. If either Party becomes aware or
has knowledge of any unauthorized use or disclosure of the other Party’s Confidential Information, it shall promptly notify the disclosing Party of such unauthorized use or disclosure. 
  
 6.5 Public Announcements. Except as set forth in press releases
published by CollaGenex and for filing a copy of this Agreement by CollaGenex with the Securities and Exchange Commission, to the extent CollaGenex determines to make such a filing, neither Party shall make any public announcement regarding this
Agreement. The Parties agree that CollaGenex may issue press releases announcing the execution of this Agreement or the activities and results hereunder in CollaGenex’s standard form, provided that such press releases shall not contain the
financial terms of Confidential Information of Skold, unless otherwise required by applicable law. 
  
 6.6 Injunctive Relief. Each Receiving Party acknowledges that the Disclosing Party or any other owner of the Confidential Information (which may
include Affiliates of CollaGenex) would suffer irreparable harm if the Receiving Party were to violate the confidentiality provisions of this Agreement and therefore the Receiving Party agrees that, in addition to any other remedies available to it,
the Disclosing Party shall be entitled (without the requirement of posting any bond) to obtain from a court of competent jurisdiction an injunction restraining the violation of this Agreement. 
  

 - 15 - 

 ARTICLE 7 
 INDEMNIFICATION 
  
 7.1
CollaGenex. CollaGenex shall defend Skold and its Affiliates at CollaGenex’s cost and expense, and will indemnify and hold Skold and its Affiliates and their respective directors, officers, employees and agents harmless from and against
any and all Losses incurred in connection with or arising out of any Third Party claim (a “Third Party Claim”) relating to (i) any material breach by CollaGenex of any of its representations, warranties, covenants or obligations
pursuant to this Agreement, or (ii) any gross negligence or willful misconduct of CollaGenex; provided, however, that in all cases referred to in this Section 7.1, CollaGenex shall have no liability to Skold for any Losses to the extent that such
Losses were caused by any item for which Skold is required to indemnify CollaGenex pursuant to Section 7.2. 
  
 7.2 Skold. Skold agrees to defend CollaGenex and its Affiliates at Skold’s cost and expense, and will indemnify and hold CollaGenex and its
Affiliates and their respective directors, officers, employees and agents harmless from and against any and all Losses incurred in connection with or arising out of any Third Party Claim relating to (i) any material breach by Skold of any of its
representations, warranties, covenants or obligations pursuant to this Agreement, or (ii) any gross negligence or willful misconduct of Skold, provided, however, that in all cases referred to in this Section 7.2, Skold shall have no liability to
CollaGenex for any Losses to the extent that such Losses were caused by any item for which CollaGenex is required to indemnify Skold pursuant to Section 7.1. 
  
 7.3 Indemnification Procedures. 
  
 (a) In the case of a Third Party Claim made by any Person who is not a Party to this Agreement (or an Affiliate thereof) as to which a Party (the
“Indemnitor”) may be obligated to provide indemnification pursuant to this Agreement, such Party seeking indemnification hereunder (“Indemnitee”) will notify the Indemnitor in writing of the Third Party Claim (and
specifying in reasonable detail the factual basis for the Third Party Claim and to the extent known, the amount of the Third Party Claim) reasonably promptly after becoming aware of such Third Party Claim; provided, however, that failure to give
such notification will not affect the indemnification provided hereunder except to the extent the Indemnitor shall have been actually prejudiced as a result of such failure. 
  
 (b) If a Third Party Claim is made against an Indemnitee and the Indemnitor acknowledges in writing its obligation to
indemnify the Indemnitee therefor, the Indemnitor will be entitled, within one hundred twenty (120) days after receipt of written notice from the Indemnitee of the commencement or assertion of any such Third Party Claim, to assume the defense
thereof (at the expense of the Indemnitor) with counsel selected by the Indemnitor and reasonably satisfactory to the Indemnitee, for so long as the Indemnitor is conducting a good faith and diligent defense. Should the Indemnitor so elect to assume
the defense of a Third Party Claim, the Indemnitor will not be liable to the Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee in connection with the defense thereof; provided, that if under applicable standards of
professional conduct a conflict of interest exists between the Indemnitor and the Indemnitee in respect of such claim, such Indemnitee shall have the right to employ separate counsel (which shall be reasonably satisfactory to the Indemnitor) to
represent 
  

 - 16 - 

 such Indemnitee with respect to the matters as to which a conflict of interest exists and in that event the reasonable
fees and expenses of such separate counsel shall be paid by such Indemnitor; provided, further, that the Indemnitor shall only be responsible for the reasonable fees and expenses of one separate counsel for such Indemnitee. If the Indemnitor assumes
the defense of any Third Party Claim, the Indemnitee shall have the right to participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the Indemnitor. If the Indemnitor assumes the defense of
any Third Party Claim, the Indemnitor will promptly supply to the Indemnitee copies of all correspondence and documents relating to or in connection with such Third Party Claim and keep the Indemnitee informed of developments relating to or in
connection with such Third Party Claim, as may be reasonably requested by the Indemnitee (including, without limitation, providing to the Indemnitee on reasonable request updates and summaries as to the status thereof). If the Indemnitor chooses to
defend a Third Party Claim, all Indemnitees shall reasonably cooperate with the Indemnitor in the defense thereof (such cooperation to be at the expense, including reasonable legal fees and expenses, of the Indemnitor). If the Indemnitor does not
elect to assume control of the defense of any Third Party Claim within the one hundred twenty (120) day period set forth above, or if such good faith and diligent defense is not being or ceases to be conducted by the Indemnitor, the Indemnitee shall
have the right, at the expense of the Indemnitor, after three (3) Business Days notice to the Indemnitor of its intent to do so, to undertake the defense of the Third Party Claim for the account of the Indemnitor (with counsel selected by the
Indemnitee), and to compromise or settle such Third Party Claim, exercising reasonable business judgment. 
  
 (c) If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee will agree to any
settlement, compromise or discharge of such Third Party Claim that the Indemnitor may recommend that by its terms obligates the Indemnitor to pay the full amount of Losses (whether through settlement or otherwise) in connection with such Third Party
Claim and unconditionally and irrevocably releases the Indemnitee completely from all liability in connection with such Third Party Claim; provided, however, that, without the Indemnitee’s prior written consent, the Indemnitor shall not consent
to any settlement, compromise or discharge (including the consent to entry of any judgment), and the Indemnitee may refuse in good faith to agree to any such settlement, compromise or discharge, that provides for injunctive or other nonmonetary
relief affecting the Indemnitee. If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee shall not (unless required by law) admit any liability with respect to, or settle,
compromise or discharge, such Third Party Claim without the Indemnitor’s prior written consent (which consent shall not be unreasonably withheld). 
  
 7.4 Insurance. Immediately upon the first administration of a Product to a human by CollaGenex, its Affiliates or its licensees, and for a period
of five (5) years after the expiration of this Agreement or the earlier termination thereof, CollaGenex shall obtain and/or maintain at its sole cost and expense, product liability insurance. Such product liability insurance shall insure both
Parties against all liability, including personal injury, physical injury, or property damage arising out of the manufacture, sale, distribution, or marketing of any Product. Upon the reasonable written request of Skold, CollaGenex shall provide
written proof of the existence of such insurance. 
  

 - 17 - 

 7.5 Limitation of Liabilities. IN NO EVENT WILL EITHER PARTY BE LIABLE TO ANY OF THE OTHER PARTY
FOR PUNITIVE, EXEMPLARY, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION LOST PROFITS, BUSINESS OR GOODWILL) ATTRIBUTABLE TO ANY BREACH OR DEFAULT BY SUCH PARTY UNDER THIS AGREEMENT. EXCEPT FOR A PARTY’S
INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 7 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT WILL EITHER PARTY’S LIABILITY EXCEED THE AMOUNTS PAID UNDER THIS AGREEMENT. THE LIMITATIONS OF LIABILITY CONTAINED SHALL SURVIVE ANY FAILURE OF THE
ESSENTIAL PURPOSE OF A LIMITED OR EXCLUSIVE REMEDY SET FORTH HEREIN. 
  
 ARTICLE 8 
 TERM AND TERMINATION 
  
 8.1 Term. Unless earlier terminated by mutual agreement of the Parties in writing or pursuant to the provisions of
this Article 8, this Agreement will continue in full force and effect on a country-by-country and Product-by-Product basis until the obligation to pay royalties and Sublicense Income payments with respect to the sale of a Product in such country
expires (the “Term”). 
  
 8.2 Voluntary
Termination by CollaGenex. Notwithstanding any other provision herein, CollaGenex may terminate this Agreement at any time after March 31, 2007. 
  
 8.3 Material Breach. Upon a material breach of this Agreement by CollaGenex on the one hand, or Skold on the other hand (in such capacity, the
“Breaching Party”), the other Party (in such capacity, the “Non-Breaching Party”) may provide written notice (a “Breach Notice”) to the Breaching Party specifying the material breach. If the
Breaching Party fails to cure such material breach during the ninety (90) day period following the date on which the Breach Notice is provided (or, if applicable, such longer period, but not to exceed one hundred and eighty (180) days, as would be
reasonably necessary for a diligent party to cure such material breach, provided the Breaching Party has commenced and continues its diligent efforts to cure during the initial ninety (90) day period), then the Non-Breaching Party may terminate this
Agreement on a Product-by-Product and country-by-country basis with respect to the Product and country to which the breach relates. 
  
 8.4 Continuing Rights of Sublicensees. Upon any termination of this Agreement, each sublicense previously granted by CollaGenex, or any of its
Affiliates, to any Person that is not an Affiliate of CollaGenex (each, an “Independent Sublicensee”) shall remain in effect and shall become a direct license or sublicense, as the case may be, of such rights by Skold to such
Independent Sublicensee, subject to the Independent Sublicensee agreeing in writing to assume CollaGenex’s terms, conditions and obligations to Skold under this Agreement as they pertain to the sublicensed rights. To the extent any Independent
Sublicensee was obligated to pay any royalties or milestones to CollaGenex under the terms of the sublicense agreement with such Independent Sublicensee, CollaGenex shall be entitled to receive fifty percent (50%) of such royalty or milestone
payments that are paid to Skold. 
  

 - 18 - 

 8.5 Effect of Termination. 
  
 (a) Termination by Skold for CollaGenex’s Breach. In the event this Agreement is terminated by Skold for a
material breach of CollaGenex pursuant to Section 8.3, on a Product-by-Product and/or country-by-country basis, as applicable, the following provisions shall apply: 
  
 (i) CollaGenex shall promptly return and/or provide to Skold all Confidential Information of Skold (or if such termination
is only with respect to a Product and/or country, shall return and/or provide all Confidential Information with respect to such Product and/or country), provided that CollaGenex shall be entitled to retain a copy for archival purposes or as
otherwise required by law; 
  
 (ii) all amounts due and payable
hereunder by CollaGenex to Skold shall be immediately paid (or if such termination is only with respect to a Product, all amounts due and payable with respect to such terminated Product shall be immediately paid); 
  
 (iii) CollaGenex shall transfer to Skold without any payment the Purchased
Assets and Additional Records relating to such terminated Product and/or country. Such transfer shall be accompanied by documentation, data and information related to the Purchased Assets that can be transferred by CollaGenex; provided that if the
Purchased Asset relates to a Product or a country that is not being terminated, CollaGenex shall not transfer such Purchased Asset but shall grant to Skold an exclusive license with respect to such Purchased Asset in connection with such terminated
Product and/or country; and 
  
 (iv) In the event that
CollaGenex, pursuant to this Section 8.5, transfers its rights to the Purchased Assets to Skold, then CollaGenex’s indemnification obligations pursuant to Section 7.1 shall survive for any Losses that arise from the development or
commercialization of the Products before the date of transfer. 
  
 (b) Voluntary Termination by CollaGenex. If CollaGenex terminates this Agreement in whole, pursuant to Section 8.2, the following provisions shall be applicable: 
  
 (i) CollaGenex shall promptly return and/or provide to Skold all Confidential Information of Skold hereunder, provided that
CollaGenex shall be entitled to retain a copy for archival purposes or as otherwise required by law; 
  
 (ii) CollaGenex shall, within six (6) months, discontinue sales of any then-existing terminated Product inventory, if not terminated by Skold for a
material breach of CollaGenex pursuant to Section 8.3; 
  
 (iii)
CollaGenex shall transfer to Skold the Purchased Assets and Additional Records relating to such terminated Products. Such transfer shall be accompanied by documentation, data and information related to the Purchased Assets that can be transferred by
CollaGenex; 
  
 (iv) In the event that CollaGenex, pursuant to
this Section 8.5, transfers its rights to the Purchased Assets to Skold, then CollaGenex’s indemnification obligations pursuant to Section 7.1 shall survive for any Losses that arise from the development or commercialization of the Products
before the date of transfer; and 
  
 (v) all amounts due and
payable by CollaGenex to Skold shall be immediately paid. 
  

 - 19 - 

 (c) Termination by CollaGenex for Skold’s Breach. In the event this Agreement is terminated
by CollaGenex for a material breach of Skold pursuant to Section 8.3, on a Product-by-Product and/or country-by-country basis, as applicable, the following provisions shall apply: 
  
 (i) Skold shall promptly return and/or provide to CollaGenex all Confidential Information of CollaGenex hereunder (or if
such termination is only with respect to a Product and/or country, shall return and/or provide all Confidential Information with respect to such Product and/or country), provided that Skold shall be entitled to retain a copy for archival purposes or
as otherwise required by law; 
  
 CollaGenex shall no longer be required to pay
any royalties or Sublicense Income payments to Skold. 
  
 (d)
Accrued Rights; Surviving Obligations. Unless explicitly provided otherwise in this Agreement, termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights, which shall have accrued to
the benefit to any Party prior to such termination, relinquishment or expiration, including damages arising from any breach hereunder. Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly
indicated to survive termination or expiration of the Agreement, including, without limitation, those obligations set forth in Sections 4.8, 6.1, 6.2, 6.3, 6.6, 8.4, and 8.5 and Articles 7 and 9. 
  
 ARTICLE 9 
 MISCELLANEOUS 
  
 9.1 Dispute Resolution; Mediation. Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination, or invalidity thereof (each, a “Dispute”) shall
first be referred by the Parties to their respective senior-level executives, or their designees, for attempted resolution through good faith negotiations. In the event that such persons cannot resolve the Dispute within thirty (30) days following
either Party’s written request to initiate such negotiations, either Party may, by written notice to the other, require that the Dispute be referred to non-binding mediation administered by the American Arbitration Association (the
“AAA”) in accordance with its then-current Commercial Mediation Rules. The presiding mediator shall have experience with disputes involving the technology that is the subject matter of this Agreement. The mediation shall be
conducted in the English language and all mediation sessions shall be held in Philadelphia, Pennsylvania. The Parties shall each be responsible for one-half of any fees or other amounts payable to the AAA or the mediator, and each Party shall bear
its own attorneys’ fees and other expenses in connection with the mediation. If efforts at mediation are unsuccessful in resolving the Dispute within thirty (30) days after the first mediation session, either Party may pursue any and all legal
or equitable remedies available to it, subject to the remaining provisions of this Agreement. The Parties agree that the procedures set forth in this paragraph shall be the sole and exclusive means of resolving any and all Disputes. Notwithstanding
the foregoing and subject to the remaining provisions of this Agreement, either Party may seek injunctive or other equitable relief in a court of competent jurisdiction pending the outcome of any negotiations or mediation conducted hereunder.

  

 - 20 - 

 9.2 Assignment. This Agreement may not be assigned or otherwise transferred (in whole or in part,
whether voluntarily, by operation of law or otherwise) by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign this Agreement, in whole
or in part, to any of its Affiliates provided that the assigning Party guarantees the performance of this Agreement by such Affiliate; and provided further, that either Party may assign this Agreement to a successor to all or substantially all of
the assets or line of business to which this Agreement relates whether by merger, sale of stock, sale of assets or other similar transaction. This Agreement shall be binding upon, and subject to the terms of the foregoing sentence, inure to the
benefit of the Parties hereto, their permitted successors, legal representatives and assigns. 
  
 9.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 
  
 9.4 Force Majeure. Neither
Party shall be liable to the other Party for loss or damages, or shall have any right to terminate this Agreement for any default or delay attributable to any Force Majeure, provided that the Party affected gives prompt notice of any such cause to
the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder for so long as it is thereby disabled from performing such obligations; provided, however, that such affected Party promptly commences
and continues to use its Commercially Reasonable Efforts to cure such disablement as soon as practicable. 
  
 9.5 Notices. Notices to Skold shall be addressed to: 
  
 Thomas Skold 
 Bjorno Gard 
 S-761 41 Norrtalje 
 Sweden 
 Facsimile No.: (0046) 176 22 4420 
  
 Notices to CollaGenex shall be addressed to: 
  
 CollaGenex Pharmaceuticals, Inc. 
 41 University Drive, Suite 200 
 Newtown, Pennsylvania 18940 
 United States of America 
 Attention: Chief Executive Officer 
 Facsimile No.: (001) 215 579 8577 
  
 Either Party may change the address to which notices shall be sent by giving notice to the other Party in the manner herein provided. Any notice required or provided for
by the terms of this Agreement shall be in writing and shall be (i) sent by registered or certified mail, return receipt requested, postage prepaid, (ii) sent via a reputable overnight courier service, or (iii) sent by facsimile transmission, in
each case properly addressed in accordance with the paragraphs above. The effective date of any notice shall be the actual date of receipt by the Party receiving the same. 
  

 - 21 - 

 9.6 Amendment. No amendment, modification or supplement of any provision of this Agreement shall
be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
  
 9.7 Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 
  
 9.8 Counterparts; Facsimile Signatures. This Agreement may be executed in counterparts and such counterparts taken together shall constitute one
and the same agreement. This Agreement may be executed by facsimile signatures, which signatures shall have the same force and effect as original signatures. 
  
 9.9 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement. 
  
 9.10
Governing Law. This Agreement shall be governed and construed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to any choice of law provisions thereof. Each Party hereby submits itself for the purpose of
this Agreement and any controversy arising hereunder to the exclusive jurisdiction of the state and federal courts located in the Commonwealth of Pennsylvania, and any courts of appeal therefrom, and waives any objection on the grounds of lack of
jurisdiction (including, without limitation, venue) to the exercise of such jurisdiction over it by any such courts. 
  
 9.11 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto
shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be
reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalid, illegal or unenforceable provisions of this Agreement shall not affect the
validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without
the invalid, illegal or unenforceable provisions. 
  
 9.12
Entire Agreement of the Parties. This Agreement hereby, together with the Schedules and Exhibits, constitute and contain the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior
negotiations, correspondence, understandings and agreements (including the Original Agreement) whether oral or written, between the Parties respecting the subject matter hereof and thereof; provided that nothing in this Agreement shall replace,
supercede, cancel or modify any prior agreements or assignments between the Parties that have been filed with the United States Patent and Trademark Office. 
  

 - 22 - 

 9.13 Independent Contractors. The relationship between the Parties created by this Agreement is
one of independent contractors and neither Party shall have the power or authority to bind or obligate the other except as expressly set forth in this Agreement. 
  
 9.14 Expenses. Unless otherwise provided herein, all costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby shall be paid by the Party which shall have incurred the same and the other Party shall have no liability relating thereto. 
  
 9.15 No Third Party Beneficiaries. No person or entity other than the Parties hereto and their respective Affiliates,
successors and permitted assigns shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. 
  
 9.16 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against either Party. 
  
 [Signature Page Immediately Follows] 
  

 - 23 - 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Agreement as
of the Effective Date. 
  

			
	THOMAS SKOLD
		
	By:	 	 /s/ Thomas Skold

	Name:	 	Thomas Skold
	
	COLLAGENEX PHARMACEUTICALS INC.
		
	By:	 	 /s/ Colin Stewart

	Name:	 	Colin Stewart
	Title:	 	Chief Executive Officer and President

  
 SIGNATURE PAGE TO ASSET PURCHASE AND PRODUCT DEVELOPMENT AGREEMENT 

 SCHEDULE 1.22 
  
 Patent Rights 
  
 The following Patent Rights have been previously assigned by Skold to CollaGenex. Skold’s representations, warranties, covenants and obligations set
forth herein shall also apply to such previously assigned Patent Rights, including those obligations set forth in Sections 2.5 and 5.2 of the Agreement. 
  

	•	Provisional application filed on March 13, 2002 (Application Serial No. 60/365,059) 

  

	•	U.S. Application Serial No. 10/388,371 filed on March 13, 2003 

  

	•	International application Serial No. PCT/US03/07752 filed on March 13, 2003 

 EXHIBIT A 
  

Patent Assignment 
  
 WHEREAS,                     , an
                     corporation, whose address is
                                        ,
(“Assignor”) is the owner of the patents and applications for patent listed on the attached Appendix A; and 
  
 WHEREAS,                     , an
                     corporation, whose address is
                                        ,
(“Assignee”) desires to acquire Assignor’s entire right, title and interest in, to and under said patents and applications, and in and to the inventions covered thereby; 
  
 NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby sell,
assign, and transfer to Assignee, its entire right, title and interest in and to, including without limitation the exclusive right to make, use and sell, the inventions disclosed in the patents and applications listed in Appendix A hereto for the
territory of the United States and its possessions and territories and all foreign countries, including all rights of priority created by said applications and patents and any provisional, non-provisional, divisional, continuation or
continuation-in-part applications that may be filed based on or related to any such applications; any patents issuing on any of the foregoing applications, and any reissues, renewals, certificates of reexamination or extensions of any of the
foregoing patents, all of the foregoing referred to herein as Patents, the same to be held and enjoyed by Assignee, for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, to the end of the term or terms for which
said patents are or may be granted, together with the right to take action for past, present and future infringements and to retain any damages obtained as a result of such action. 
  
 Assignor shall at the reasonable request of Assignee and at the expense of Assignor, prepare and execute or have executed
all documents, papers, forms or authorizations, necessary or useful to vest full title in and to the Patents and inventions disclosed in the Patents, to Assignee. 
  

			
	[ASSIGNOR]
	By:	 	  

	Name:	 	  

	Title:	 	  

 Appendix A 
  

I. Issued and Granted Patents 
  
 Patent No.         Country 
  
 II. Pending Applications 
  
 Patent Application No.         Country 

 EXHIBIT B 
  

Trademark Assignment 
  
 WHEREAS,                     , an
                     corporation, whose address is
                                        ,
(“Assignor”) is the owner of the trademarks listed on the attached Appendix A (the “Marks”) and the registrations and applications for registration pertaining thereto; and 
  
 WHEREAS,
                    , an
                     corporation, whose address is
                                        ,
(“Assignee”) desires to acquire Assignor’s entire right, title and interest in, to and under said Marks and the registrations and applications for registration pertaining thereto. 
  
 NOW, THEREFORE, for good and valuable consideration, the receipt of which is
hereby acknowledged, Assignor hereby irrevocably assigns, transfers, and conveys unto Assignee all of its rights, title and interest in and to the Marks, whether statutory or at common law, including all registrations thereof and applications for
registration pertaining thereto, together with the goodwill of the business symbolized by the Marks, and the right to take action for past, present and future infringements of rights in the Marks and to retain any damages obtained as a result of
such action. 
  
 Assignor shall at the reasonable request of
Assignee, and at the expense of Assignor, prepare and execute or have executed all further documents, papers, forms or authorizations necessary or useful to vest full title in and to the Marks and the goodwill of the business in which the Marks have
been used by the Assignor to Assignee 
  

			
	[ASSIGNOR]
	By:	 	  

	Name:	 	  

	Title:	 	  

 APPENDIX A 
  

													
	 Mark

	 	 App. No.

	 	 Reg. No.

	  	 Filing Date

	  	 Reg. Date

	  	 Country

	  	 Class

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]